This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.90, marking a +1.6% move from the previous day.
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
by Zacks Equity Research
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
by Zacks Equity Research
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
by Zacks Equity Research
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Brian Big Idea On Technical Analysis
by Brian Bolan
A look at three stocks where technical analysis can help and the TAZR service.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.